Search Patents
  • CORONAVIRUS VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
    Publication number: 20230096093
    Abstract: The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
    Type: Application
    Filed: June 5, 2022
    Publication date: March 30, 2023
    Applicant: Sichuan Clover Biopharmaceuticals, Inc.
    Inventors: Peng LIANG, Joshua LANG
  • CHIMERIC CORONAVIRUS S PROTEIN COMPOSITIONS AND METHODS OF USE
    Publication number: 20240018191
    Abstract: This invention relates to chimeric coronavirus S proteins and methods of their use, for example, to treat and/or prevent diseases or disorders caused by infection by a coronavirus.
    Type: Application
    Filed: October 27, 2021
    Publication date: January 18, 2024
    Inventors: Ralph S. Baric, David R. Martinez
  • CORONAVIRUS VACCINE THROUGH NASAL IMMUNIZATION
    Publication number: 20240123053
    Abstract: The invention generally discloses coronavirus vaccine for coronavirus disease. Particularly, the invention discloses coronavirus vaccine through nasal immunization. More particularly, the invention describes and develop a preventive vaccine against infection or disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through nasal immunization in mammals. Specifically, the invention describes human adenovirus which is engineered to express SARS-CoV-2 spike protein or part/fragment thereof which elicit immune response against the SARS-CoV-2 in mammals, and it is also suitable for immunizing human subjects. Describes the method of production of novel adenovirus vectors, use thereof in vaccine composition, vaccine formulation, preparation, and method of treatment of COVID-19 using above said novel vectors and compositions thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: April 18, 2024
    Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Krishna Murthy ELLA, Krishna Mohan VADREVU, Raches ELLA, Raju SUNAGAR
  • CORONAVIRUS-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES, AND COMPOSITION COMPRISING SAME FOR PREVENTING AND TREATING CORONAVIRUS DISEASE-19
    Publication number: 20230295633
    Abstract: The present disclosure relates to a coronavirus-specific double-stranded oligonucleotide and a use thereof. The present disclosure induces RNA interference specific to a coronavirus, particularly, to SARS-CoV, SARS-CoV-2, and a mutant thereof so as to effectively inhibit viral infection and proliferation, and is nearly unaffected by viral variants since a conserved sequence is mainly targeted. Therefore, the double-stranded oligonucleotide of the present disclosure may be effectively used in proliferation inhibition, infection prevention, and disease treatment of the coronavirus, and particularly, may be effectively used as an agent for preventing and treating COVID-19, which is the cause of the current pandemic.
    Type: Application
    Filed: June 25, 2021
    Publication date: September 21, 2023
    Inventors: Se Hun GU, Chi Ho YU, Youngjo SONG, Dong Hyun SONG, Gyeung Haeng HUR, Seong Tae JEONG, Jun Young CHOI, Na Young KIM, Euni SIM, Seung Hyeop LEE
  • Methods For Treating Coronavirus Disease
    Publication number: 20230094263
    Abstract: Provided herein are methods for treating coronavirus diseases. In one embodiment, the method comprises administering to a coronavirus disease patient a therapeutic amount of decidua stromal cells. In one embodiment, the method comprises administering to the subject a therapeutic amount of decidua stromal cells (DSCs). In some embodiments, the coronavirus disease is SARS, MERS or COVID-19. The method of the disclosure can be used to treat a subject who has acute respiratory distress syndrome (ARDS), acute lung injury (ALI), or both.
    Type: Application
    Filed: May 3, 2021
    Publication date: March 30, 2023
    Inventor: Behnam Sadeghi
  • COMPOSITIONS AND METHODS FOR TARGETING THE INTERACTION OF HOST MYO5B+D AND CORONAVIRUS M PROTEINS
    Publication number: 20240000885
    Abstract: Disclosed herein is a method for treating or preventing a coronavirus infection in a subject that involves administering to the subject an effective amount of a composition comprising an agent that disrupts the binding of coronavirus membrane glycoprotein (M protein) and Myosin Vb protein (MYO5B). Also disclosed herein is a method for identifying an agent for treating or preventing a coronavirus infection that involves providing a system comprising coronavirus membrane glycoprotein (M protein) and human Myosin Vb protein (MYO5B) with conditions suitable for binding of the M protein and MYO5B; contacting the system with a candidate agent; and assaying the system for binding of M protein and MYO5B.
    Type: Application
    Filed: November 3, 2021
    Publication date: January 4, 2024
    Inventors: Frédéric TANGY, Pierre-Olivier VIDALAIN, James R. GOLDENRING, Joseph T. Roland, Lynne A. LAPIERRE, Elizabeth MANNING, Cornelis Alexander Maria DE HAAN
  • Nucleic Acid Detection Kit For Novel Coronavirus 2019-nCoV
    Publication number: 20230070496
    Abstract: Provided is a nucleic acid detection kit for novel coronavirus 2019-nCoV, and in particular, provided are a kit and a method for multiple detection of the nucleic acid of the novel coronavirus 2019-nCoV. Three nucleic acid targets of the novel coronavirus 2019-nCoV can be detected at the same time. False positives can be prevented by means of mutual authentication among different targets, and detection omissions, which may be caused by mutations, are confirmed, such that the accuracy of virus identification is significantly improved.
    Type: Application
    Filed: December 30, 2020
    Publication date: March 9, 2023
    Inventors: Xiwen JIANG, Jian FAN, Hailong PENG
  • Coronavirus vaccine
    Patent number: 11925694
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 12, 2024
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME
    Publication number: 20230355745
    Abstract: Disclosed are a novel coronavirus-derived receptor-binding domain variant having reduced ACE2-binding affinity, a fusion protein comprising the same, and the use thereof. It is possible to overcome the drawbacks of conventional vaccines using the coronavirus spike protein or receptor-binding domain thereof, wherein the reduced ACE2 expression due to binding to ACE2 and negative feedback may lead to side effects of the lungs or heart, and in particular, may be fatal to patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein constructed by fusing the coronavirus receptor-binding domain with the Fc domain is imparted with a greatly improved in-vivo half-life, and has superior efficacy by further combining N protein, M protein, ORF protein, or the like of SARS-CoV-2 therewith through additional modification and thus is highly applicable to a multivalent immunogenic composition.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 9, 2023
    Inventors: Myoung Ho JANG, Jae Chan PARK, Young Joo CHOI, Young Hyun PARK, Gil-Jung KIM, Seung Mi JEONG, Yeon Soo PARK, Su Bin LEE
  • VIRAL VACCINE COMPOSITIONS FOR INOCULATING A SUBJECT AGAINST A CORONAVIRUS, AN INFLUENZA VIRUS, OR BOTH
    Publication number: 20230364221
    Abstract: Described herein are viral vaccine compositions for inoculating a subject against a coronavirus, an influenza virus, or both. The viral vaccine compositions may contain coronavirus antigens, influenza virus antigens, or both to elicit a sustained immune response in the subject. A viral vaccine may be formulated for nasal delivery. Also described herein are methods of administering viral vaccine compositions to a subject to prevent a coronavirus infection, influenza, or both. The viral vaccine compositions may be administered intranasally and may elicit an antigen-specific mucosal immune response in the subject.
    Type: Application
    Filed: October 14, 2021
    Publication date: November 16, 2023
    Inventor: Steven C. QUAY
  • Use of Bromophenol-pyrazoline Compounds in the Treatment of Porcine Coronavirus Diseases
    Publication number: 20220193036
    Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.
    Type: Application
    Filed: September 17, 2021
    Publication date: June 23, 2022
    Inventors: Dayong Shi, Xiangqian Li, Xin Wang, Jinbo Yang, Feng Xu, Rong Zhang
  • SILVER NANOPARTICLES FOR USE IN INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20230158067
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: April 6, 2021
    Publication date: May 25, 2023
    Inventor: Ankit Agarwal
  • DETECTION ASSAYS FOR CORONAVIRUS NEUTRALIZING ANTIBODIES
    Publication number: 20230184765
    Abstract: The disclosure provides methods for determining the presence of coronavirus neutralizing antibodies in a sample as well as associated compositions and kits. The methods of the disclosure use recombinant vesicular stomatitis virus (VSV) particles, wherein the VSV glycoprotein (G) is replaced by a coronavirus spike (S) glycoprotein or a fragment or a derivative thereof. In a specific embodiment, the S glycoprotein is derived from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) and the methods are used for determining the presence of SARS-CoV-2 neutralizing antibodies.
    Type: Application
    Filed: April 19, 2021
    Publication date: June 15, 2023
    Applicant: VYRIAD, INC.
    Inventors: Stephen J. RUSSELL, Kah Whye PENG, Patrycja LECH, Rianna VANDERGAAST, Timothy CAREY
  • SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES
    Publication number: 20230323389
    Abstract: Disclosed are synthetic modified vaccinia ankara (MVA)-based vaccines for preventing or treating coronavirus infections and methods of producing the vaccines. Specifically, the disclosure provides a vaccine composition comprising: (i) a single synthetic DNA fragment or two or more synthetic DNA fragments comprising the entire genome of an MVA, and (ii) one or more DNA sequences encoding one or more coronavirus antigens, subunits, or fragments thereof, inserted in one or more insertion sites of the MVA for preventing or treating coronavirus infections.
    Type: Application
    Filed: May 17, 2021
    Publication date: October 12, 2023
    Applicant: CITY OF HOPE
    Inventors: Don J. DIAMOND, Felix WUSSOW, Flavia CHIUPPESI
  • CORONAVIRUS DIAGNOSTIC COMPOSITIONS, METHODS, AND USES THEREOF
    Publication number: 20230243827
    Abstract: The present disclosure discloses recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides, useful for analyzing an analyte such as neutralizing antibodies. In some aspects, the recombinant peptides and proteins comprise a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. Diagnostic methods and related kits are also disclosed.
    Type: Application
    Filed: June 10, 2021
    Publication date: August 3, 2023
    Applicant: Sichuan Clover Biopharmaceuticals, Inc.
    Inventors: Peng LIANG, Joshua LIANG
  • Coronavirus vaccine compositions, methods, and uses thereof
    Patent number: 11389528
    Abstract: The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: July 19, 2022
    Assignee: Sichuan Clover Biopharmaceuticals, Inc
    Inventors: Peng Liang, Joshua Liang
  • METHODS AND COMPOSITIONS FOR TREATMENT OF CORONAVIRUS INFECTION
    Publication number: 20230137667
    Abstract: The present invention provides methods and compositions for treating coronavirus infection and diseases and disorders associated with or caused by coronavirus infection.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 4, 2023
    Inventors: Ralph Baric, Amy Sims, Hugh D. Mitchell, Katrina M. Waters
  • COBICISTAT FOR PREVENTION AND/OR TREATMENT OF CORONAVIRUS INFECTIONS
    Publication number: 20230107186
    Abstract: The present invention relates to cobicistat and its derivatives or prodrugs for use in the prophylaxis and/or treatment of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, severe acute respiratory syndrome coronavirus (SARS-CoV) infection and/or Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The present invention further relates to methods of prevention and/or treatment of SARS-CoV-2 infection.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 6, 2023
    Inventors: MOHAMED OMAR FARES, MAHMOUD MOSTAFA TOLBA, AHMED TAHA AYOUB, MARINA LUSIC, IART LUCA SHYTAJ, ANDREA SAVARINO, RICARDO SOBHIE DIAZ
  • SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20230128687
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: March 31, 2021
    Publication date: April 27, 2023
    Inventor: Jan Remmereit
  • SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION
    Publication number: 20240148763
    Abstract: The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Inventor: Jan Remmereit
Narrow Results

Filter by US Classification